BTBP(SH:600161)2018-07-19 16:00Financial Performance - Total operating revenue for the first half of 2018 was CNY 122,028.92 million, an increase of 18.17% compared to CNY 103,264.35 million in the previous year[3] - Net profit attributable to shareholders of the listed company decreased by 72.63% to CNY 24,117.14 million from CNY 88,104.03 million in the same period last year[3] - Operating profit fell by 59.83% to CNY 41,790.70 million, down from CNY 104,027.69 million year-on-year[3] - Basic earnings per share decreased to CNY 0.28 from CNY 1.01, reflecting a decline of 72.63%[3] - The weighted average return on net assets dropped to 6.40%, down 20.30 percentage points from 26.70%[3] Assets and Liabilities - Total assets at the end of the reporting period were CNY 467,079.26 million, a decrease of 11.20% from CNY 525,996.81 million at the beginning of the period[3] Business Segments - The net profit from blood products business increased by 70.04% to CNY 24,117.14 million compared to CNY 14,183.62 million in the previous year[7] - The company expects significant profit increases from the blood products business due to improved production and sales after the integration of three blood product companies[5] One-time Events - The company reported a substantial decrease in operating profit and net profit due to the previous year's one-time investment gains of CNY 758 million from the sale of stakes in two companies[5] Cautionary Notes - The financial data for the first half of 2018 is preliminary and has not been audited, highlighting the need for caution among investors[6]